Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Novartis Ag ADR (NY: NVS ) 109.35 +0.95 (+0.88%) Official Closing Price Updated: 7:00 PM EDT, Nov 1, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Novartis Ag ADR < Previous 1 2 3 4 5 6 7 8 9 ... 29 30 Next > Stock Market Retreats Before Election Day; Microsoft, Apple, Amazon, Google, Meta In Focus: Weekly Review Today 12:27 EDT The major indexes declined, but haven't fallen apart. Via Investor's Business Daily Is NYSE:NVS suited for dividend investing? Today 6:10 EDT Uncovering Dividend Opportunities with NOVARTIS AG-SPONSORED ADR (NYSE:NVS). Via Chartmill Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights October 30, 2024 Novartis aims to enhance Pluvicto's market presence while exploring growth in multiple sclerosis and expanding its radioligand therapy portfolio. Via Benzinga Novartis Reports Q3 Momentum, But Shares Lose Support October 29, 2024 Novartis stock slipped Tuesday, despite a solid Q3 performance and an upgraded outlook. Via Investor's Business Daily Looking Into Novartis's Recent Short Interest October 14, 2024 Via Benzinga Why NYSE:NVS is a Top Pick for Dividend Investors. October 09, 2024 Exploring NOVARTIS AG-SPONSORED ADR (NYSE:NVS)'s dividend characteristics. Via Chartmill Lyell Immunopharma Downgraded, Analyst Flags Concerns Over Acquisition Strategy October 30, 2024 Lyell Immunopharma acquires ImmPACT Bio, ends TIL programs, and refocuses on CAR T-cell research. Analyst downgrades reflect concerns over pipeline complexities. Via Benzinga Novartis Ag (NVS) Q3 2024 Earnings Call Transcript October 29, 2024 NVS earnings call for the period ending September 30, 2024. Via The Motley Fool Topics Earnings Exposures Financial Novartis Q3 Earnings Beats Expectations On Strong Sales From Key Drugs, Lifts 2024 Outlook October 29, 2024 Novartis reported strong third-quarter sales of $12.823 billion, beating consensus, with key growth drivers contributing to momentum and upgraded guidance for 2024. Via Benzinga Topics Earnings Exposures Financial Monte Rosa Stock Doubles — Up 127% — On A Massive Deal With Novartis October 28, 2024 The companies will collaborate on a molecular glue degrader, a potential treatment for autoimmune diseases. Via Investor's Business Daily Why Is Monte Rosa Therapeutics Stock Surging On Monday? October 28, 2024 Monte Rosa Therapeutics stock rises as it announces a global licensing deal with Novartis to advance MRT-6160 for immune conditions. Via Benzinga Balancing Dividends and Fundamentals: The Case of NYSE:NVS. September 13, 2024 Why NOVARTIS AG-SPONSORED ADR (NYSE:NVS) provides a good dividend, while having solid fundamentals. Via Chartmill 3 Absurdly Cheap Stocks That Pay High Dividends October 24, 2024 These stocks are trading at less than 15 times their expected future profits. Via The Motley Fool After US Senator, Unions Urge Federal Trade Commission To Block Novo's $16.5B Acquisition Of Catalent October 18, 2024 Public interest groups are urging the FTC to block Novo Holdings' $16.5 billion acquisition of Catalent, citing concerns over reduced competition in critical areas like diabetes, obesity treatments,... Via Benzinga European Medicines Agency's Panel Supports Approval Of Novartis' Kisqali In Patients With Early-Breast Cancer October 18, 2024 Novartis' Kisqali receives a positive recommendation from EMA's CHMP for adjuvant treatment of early breast cancer, showing a significant reduction in cancer recurrence in a Phase 3 trial. European... Via Benzinga 1 Healthcare Giant That Isn't Jumping on the GLP-1 Bandwagon, and Why That Could Be a Great Move October 17, 2024 Novartis is taking a more calculated and strategic approach to its growth. Via The Motley Fool Syfovre's Competitive Edge Highlights Bright Future For Apellis Pharmaceuticals, Analyst Initiates With Bullish Pitch October 16, 2024 William Blair initiates coverage of Apellis Pharmaceuticals, highlighting its innovative therapies for complement C3 targeting. The analyst forecasts significant growth opportunities with peak sales... Via Benzinga 2 Magnificent Dividend Stocks to Buy and Hold Forever October 14, 2024 These companies have compelling track records. Via The Motley Fool Recently Listed Cancer Firm OnKure's Innovative Approach to Breast Cancer Treatment Sparks Analyst Enthusiasm October 10, 2024 OnKure Therapeutics has garnered attention following its merger with Reneo Pharmaceuticals and a $65 million private placement. Oppenheimer initiated coverage with an Outperform rating, highlighting... Via Benzinga Bristol-Myers Squibb's Profits, Stock Price Kick Into High Gear October 03, 2024 A Relative Strength Rating upgrade for Bristol Myers Squibb shows improving technical performance. Will it continue? Via Investor's Business Daily US HHS Reveal Cost Savings For 54 Prescription Drugs Including Novartis' Cancer Drug, Ozempic Could be Next October 01, 2024 HHS announced lower costs for 54 Medicare Part B drugs starting in October 2024, part of the Inflation Reduction Act's rebate program, which aims to curb rising drug prices and reduce out-of-pocket... Via Benzinga Topics Economy Exposures Interest Rates The Importance of Managing Bad Cholesterol: What You Should Know September 27, 2024 (BPT) - Sponsored by Novartis Pharmaceuticals Corporation Via Brandpoint 2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure? September 19, 2024 Pharma stock have been on the rise in the latter half of the year, but the 2024 election remains a wild card for shares. Via Investor's Business Daily Incyte Downgraded - Analyst Notes Intense Competition, Particularly In Larger Markets September 18, 2024 Truist Securities has downgraded Incyte due to concerns over Jakafi's patent expiration in 2028. Jakafi, Incyte's top-selling drug, faces potential revenue decline amid generic competition. Truist... Via Benzinga Topics Intellectual Property Exposures Intellectual Property Novartis' Multiple Sclerosis Drug Data Shows Most Patients Remain With No Disability Progression For Up To Six Years September 18, 2024 Novartis' new data for Kesimpta showed reduced disability progression in relapsing multiple sclerosis patients. Continuous Kesimpta treatment led to better outcomes compared to those who switched from... Via Benzinga Time To Invest And Or Trade In Bio-Tech Stocks? September 13, 2024 Biotechnology stocks and biotech exchange-traded funds ETFs once played a significant role in growth equity rallies, but today it seems like those days are in the past. Will an interest rate cut help... Via Talk Markets Topics ETFs This Novartis Analyst Is No Longer Bullish; Here Are Top Downgrades For Wednesday September 11, 2024 Via Benzinga Domino's Pizza To $510? Here Are 10 Top Analyst Forecasts For Wednesday September 11, 2024 Via Benzinga Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst September 09, 2024 HC Wainwright initiated coverage on Enliven Therapeutics, noting its innovative small molecules for tumor treatments. HC Wainwright gave a Buy rating with a $37 price target, projecting significant... Via Benzinga Goldman Sachs Shifts Stance On Novartis, Cites Lack Of Near-Term Catalysts September 05, 2024 Goldman Sachs downgrades Novartis to Neutral, citing a lack of immediate innovative catalysts and limited stock growth potential. Via Benzinga < Previous 1 2 3 4 5 6 7 8 9 ... 29 30 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
